HK1076711A1 - Chimeric cd154 - Google Patents

Chimeric cd154

Info

Publication number
HK1076711A1
HK1076711A1 HK05107749.4A HK05107749A HK1076711A1 HK 1076711 A1 HK1076711 A1 HK 1076711A1 HK 05107749 A HK05107749 A HK 05107749A HK 1076711 A1 HK1076711 A1 HK 1076711A1
Authority
HK
Hong Kong
Prior art keywords
chimeric
human
sequence encoding
vector
polynucleotide sequence
Prior art date
Application number
HK05107749.4A
Other languages
English (en)
Inventor
Charles E Prussak
Thomas J Kipps
Mark J Cantwell
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of HK1076711A1 publication Critical patent/HK1076711A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Detergent Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polyoxymethylene Polymers And Polymers With Carbon-To-Carbon Bonds (AREA)
HK05107749.4A 2002-05-23 2005-09-02 Chimeric cd154 HK1076711A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/154,759 US7495090B2 (en) 2002-05-23 2002-05-23 Nucleic acids encoding chimeric CD154 polypeptides
PCT/US2003/016305 WO2003099340A1 (en) 2002-05-23 2003-05-23 Novel chimeric cd154

Publications (1)

Publication Number Publication Date
HK1076711A1 true HK1076711A1 (en) 2006-01-27

Family

ID=29548954

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05107749.4A HK1076711A1 (en) 2002-05-23 2005-09-02 Chimeric cd154

Country Status (14)

Country Link
US (3) US7495090B2 (pt)
EP (1) EP1509253B1 (pt)
JP (1) JP4454493B2 (pt)
CN (1) CN100482283C (pt)
AT (1) ATE458058T1 (pt)
AU (1) AU2003231819B2 (pt)
CA (1) CA2486918C (pt)
DE (1) DE60331307D1 (pt)
DK (1) DK1509253T3 (pt)
ES (1) ES2341331T3 (pt)
HK (1) HK1076711A1 (pt)
IL (1) IL165347A (pt)
PT (1) PT1509253E (pt)
WO (1) WO2003099340A1 (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070771B1 (en) * 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
US7786282B2 (en) * 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
US7495090B2 (en) * 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
DK2066339T3 (da) * 2006-09-18 2014-11-03 Univ Arkansas Sammensætninger og fremgangsmåder til forstærkning af immunreaktioner
US20080318886A1 (en) * 2006-12-05 2008-12-25 Prussak Charles E Methods of Increasing Cancer Sensitivity to Chemotherapeutic Agents Using Chimeric ISF35
CN102037135A (zh) * 2007-10-30 2011-04-27 阿肯色大学评议会 增强对有鞭毛的细菌的免疫反应的组合物和方法
CA3156538C (en) * 2007-11-01 2023-12-12 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to eimeria
ES2643646T3 (es) 2010-01-21 2017-11-23 The Board Of Trustees Of The University Of Arkansas Vectores de vacuna y métodos para potenciar las respuestas inmunitarias
EP2579901B1 (en) 2010-06-09 2019-08-07 The Board of Trustees of The University of Arkansas Vaccine and methods to reduce campylobacter infection
EP3421487B1 (en) 2010-10-19 2023-06-28 The Regents of the University of Colorado, a body corporate Peptides for modulating t-cell activity and uses thereof
US20150368620A1 (en) * 2013-01-30 2015-12-24 King Abdullah University Of Science And Technology Method of detaching adherent cells for flow cytometry
NZ711019A (en) 2013-02-14 2019-07-26 Univ Arkansas Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
BR112015023024B1 (pt) 2013-03-15 2022-04-19 The Board Of Trustees Of The University Of Arkansas Vetor de vacina e composições farmacêuticas compreendendo o mesmo
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
EP4245376A3 (en) 2014-10-14 2023-12-13 Novartis AG Antibody molecules to pd-l1 and uses thereof
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
EP3328418A1 (en) 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
LT3317301T (lt) 2015-07-29 2021-07-26 Novartis Ag Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3
MX2018001522A (es) 2015-08-05 2018-03-15 Janssen Biotech Inc Anticuerpos anti-cd154 y metodos de uso de estos.
US11594135B2 (en) 2015-11-02 2023-02-28 Memgen, Inc. Methods of CD40 activation and immune checkpoint blockade
US20180244750A1 (en) * 2015-11-02 2018-08-30 Memgen, Llc Methods for treatment of cancer
MX2018007423A (es) 2015-12-17 2018-11-09 Novartis Ag Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas.
WO2017192671A1 (en) 2016-05-03 2017-11-09 The Board Of Trustees Of The University Of Arkansas Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same
AU2017379835A1 (en) 2016-12-21 2019-07-11 Dnatrix Armed replication-competent oncolytic adenoviruses
US11298420B2 (en) 2016-12-21 2022-04-12 Memgen, Llc Armed oncolytic viruses
US20200353044A1 (en) * 2017-04-12 2020-11-12 Memgen, Llc Methods of cd40 and toll like receptor immune activation
AU2019205328A1 (en) * 2018-01-05 2020-08-06 Op-T Llc Therapeutic peptides and methods for treating autoimmune related disease
WO2019246111A1 (en) * 2018-06-19 2019-12-26 H. Lee Moffitt Cancer Center And Research Institute, Inc. Oncolytic virus or antigen presenting cell mediated cancer therapy using type i interferon and cd40-ligand
CN114174327A (zh) 2019-03-08 2022-03-11 黑曜石疗法公司 用于可调整调控的cd40l组合物和方法
US11793854B2 (en) 2019-03-21 2023-10-24 Op-T Llc Methods for reducing symptoms of multiple sclerosis using a six-amino acid long peptide that inhibits CD40-CD150 interaction
BR112021025022A2 (pt) 2019-06-12 2022-02-22 Obsidian Therapeutics Inc Composições de ca2 e métodos para regulação ajustáveis
MX2023002969A (es) * 2020-09-11 2023-07-11 Mark J Cantwell Mejora de la inmunidad usando un ligando quimerico del cumulo de diferenciacion 40 (cd40) y vacuna contra el coronavirus.
WO2022060904A1 (en) 2020-09-16 2022-03-24 Obsidian Therapeutics, Inc. Compositions and methods for expression of t-cell receptors with small molecule-regulated cd40l in t cells

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US22017A (en) * 1858-11-09 Pen-fountain
US2002A (en) * 1841-03-12 Tor and planter for plowing
ATE87007T1 (de) 1987-05-29 1993-04-15 Sagami Chem Res Fusionsprotein, enthaltend lymphotoxin.
DK0491878T3 (da) 1989-08-16 1997-06-23 Chiron Corp Præparater til inhibering af proteinhormondannelse og anvendelser deraf
US5716805A (en) 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US5962406A (en) 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
DK0667901T4 (da) 1991-10-25 2008-11-10 Immunex Corp Hidtil ukendt cytokin
AU5010793A (en) 1992-08-21 1994-03-15 Schering Corporation Human interleukin-13
CA2153806C (en) 1993-01-22 2005-11-08 Melanie K. Spriggs Detection and treatment of mutations in a cd40 ligand gene
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US5861310A (en) * 1993-11-03 1999-01-19 Dana-Farber Cancer Institute Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor
JPH08127594A (ja) 1993-11-10 1996-05-21 Mochida Pharmaceut Co Ltd Ｆａｓ抗原に結合する新規蛋白質およびそれをコードするＤＮＡ
AU1059095A (en) 1993-11-24 1995-06-13 Australian National University, The Treatment of viral disease with cd40l peptide
DE69535719T2 (de) 1994-01-07 2009-03-19 Mochida Pharmaceutical Co. Ltd. Fas-antigenbindender ligand
MX9605088A (es) * 1994-04-28 1997-08-30 Boehringer Ingelheim Pharma Metodos para proliferar y diferenciar celulas b y sus usos.
US5759536A (en) 1994-05-27 1998-06-02 University Technology Corporation Use of fas ligand to supress T-lymphocyte-mediated immune responses
GB9425060D0 (en) 1994-12-13 1995-02-08 Univ Birmingham Carcinoma treatment
US5888764A (en) 1995-01-20 1999-03-30 Uab Research Foundation Human fas gene promoter region
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US7070771B1 (en) * 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
DE69841548D1 (de) 1997-09-17 2010-04-22 Mochida Pharm Co Ltd Fas-liganden derivate
US6451759B1 (en) * 1998-01-14 2002-09-17 The Regents Of The University Of California Noncleavable Fas ligand
US7300774B1 (en) * 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
WO2001078769A2 (en) 2000-04-12 2001-10-25 University Of South Florida Regulation of systemic immune responses utilizing soluble cd40
US7495090B2 (en) * 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
GB2392158B (en) * 2002-08-21 2005-02-16 Proimmune Ltd Chimeric MHC protein and oligomer thereof

Also Published As

Publication number Publication date
DE60331307D1 (de) 2010-04-01
JP4454493B2 (ja) 2010-04-21
US8138310B2 (en) 2012-03-20
ATE458058T1 (de) 2010-03-15
US20030220473A1 (en) 2003-11-27
PT1509253E (pt) 2010-05-21
CA2486918C (en) 2013-08-27
EP1509253A1 (en) 2005-03-02
DK1509253T3 (da) 2010-06-07
WO2003099340A1 (en) 2003-12-04
CA2486918A1 (en) 2003-12-04
AU2003231819A1 (en) 2003-12-12
CN1671423A (zh) 2005-09-21
US20110177556A1 (en) 2011-07-21
US20100297695A1 (en) 2010-11-25
CN100482283C (zh) 2009-04-29
US7495090B2 (en) 2009-02-24
IL165347A0 (en) 2006-01-15
IL165347A (en) 2012-05-31
JP2005537785A (ja) 2005-12-15
AU2003231819B2 (en) 2008-07-10
EP1509253B1 (en) 2010-02-17
EP1509253A4 (en) 2005-12-21
ES2341331T3 (es) 2010-06-18
US7928213B2 (en) 2011-04-19

Similar Documents

Publication Publication Date Title
HK1076711A1 (en) Chimeric cd154
WO2002095014A3 (en) Polypeptides having cellobiase activity and polynucleotides encoding same
PT1240325E (pt) Polipéptidos homólogos de il-17 e il-17r e suas utilizações terapêuticas
IL161769A0 (en) Anbtimicrobial polypeptides from pseudoplectania nigrella
WO2003000941A3 (en) Polypeptides having cellobiohydrolase i activity and polynucleotides encoding same
ATE352626T1 (de) Polypeptide mit galaktoseoxidaseaktivität und dafür kodierende nukleisäuren
UA97946C2 (ru) Моноклональное антитело, специфически связывающееся с внеклеточным доменом ilt7 человека
UA92580C2 (ru) Антитело, которое специфически связывается с cd22, и его терапевтическое и диагностическое применение
DK1131444T3 (da) Polypeptider med lysophospholipase aktivitet og nucleinsyre som koder for disse
AU2003238444A1 (en) The frog prince, a transposon vector for gene transfer in vertebrates
MX2022008955A (es) Variantes de mananasas y polinucleotidos que las codifican.
DK1756273T3 (da) Signalpeptid til frembringelse af et polypeptid
NO20085086L (no) Fettsyresyntetase, polynukleotid som koder denne og anvendelse derav
NO940655L (no) N-Acetylglukosamintransferase V kodende sekvenser
EP0972054A4 (en) INCREASING IMMUNE RESPONSE USING TARGETED MOLECULES
KR100717353B1 (ko) 피키아 파스토리스 유래의 자동 유도성 ｎｐｓ 프로모터 및이를 이용한 이종 단백질의 제조방법
WO2005021578A3 (en) A novel chimeric polypeptide and use thereof
IL111608A0 (en) Tyrosinase-activator protein fusion enzyme
MXPA05011595A (es) Composiciones de spex y metodos de uso.
SG161106A1 (en) Inhibitor proteins of a protease and use thereof
EP1572133A4 (en) METHOD FOR IDENTIFYING MODULATORS OF THE HUMAN OREXIN-2 RECEPTOR
MX2023001888A (es) Variantes de una xiloglucanasa de la familia 44.
Wittenbrink et al. Differential NKG2D binding to highly related human NKG2D ligands ULBP2 and RAET1G is determined by a single amino acid in the α2 domain
TW200801181A (en) GPR22 and methods relating thereto
DK1226236T3 (da) Polypeptider, der har glucanotransferase-aktivitet, og nucleinsyrer, som koder disse

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20230518